MARKET

ABUS

ABUS

Arbutus Biopharm
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.070
-0.130
-4.06%
After Hours: 3.050 -0.02 -0.65% 17:31 04/16 EDT
OPEN
3.200
PREV CLOSE
3.200
HIGH
3.200
LOW
3.020
VOLUME
2.00M
TURNOVER
--
52 WEEK HIGH
9.02
52 WEEK LOW
1.010
MARKET CAP
295.75M
P/E (TTM)
-3.0642
1D
5D
1M
3M
1Y
5Y
Introducing Arbutus Biopharma (NASDAQ:ABUS), The Stock That Zoomed 167% In The Last Year
Arbutus Biopharma Corporation ( NASDAQ:ABUS ) shareholders might be concerned after seeing the share price drop 18% in...
Simply Wall St. · 2d ago
Overview of the RNAi for Therapeutic Market Trends, Size, Growth, Porters, PESTEL, Analysis and Forecast By 2028
Apr 14, 2021 (Market Insight Reports) -- New Analysis Of RNAi for Therapeutic Market overview, spend analysis, imports, segmentation, key players and...
Market Insight Reports · 4d ago
Ebola Treatment Market, Application Analysis, Share, Regional Outlook, Competitive Strategies & Forecast up to 2026
Apr 13, 2021 (Market Insight Reports) -- Latest Ebola Treatment Market Analysis - 2021-2026 The report titled Global Ebola Treatment Market showcases an...
Market Insight Reports · 4d ago
Thinking about buying stock in Rigel Pharmaceuticals, Checkpoint Therapeutics, GT Biopharma, ICICI Bank, or Arbutus Biopharma?
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for RIGL, CKPT, GTBP, IBN, and ABUS.
PR Newswire - PRF · 5d ago
Thinking about buying stock in Arbutus Biopharma, BrightSphere Investment Group, Commscope Holding, Gogo Inc, or Jaguar Health?
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ABUS, BSIG, COMM, GOGO, and JAGX.
PR Newswire - PRF · 04/08 12:35
RNA Therapy Market Research Report by Technology, by Application, by End User - Global Forecast to 2025 - Cumulative Impact of COVID-19
New York, April 08, Apr 08, 2021 (GLOBE NEWSWIRE via COMTEX) -- New York, April 08, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the...
GlobeNewswire · 04/08 11:52
4 Penny Stocks To Buy Now With Price Targets Up To 302%
Apr 02, 2021 (Penny Stocks via COMTEX) -- Analysts Say Buy These Penny Stocks; Do You Agree? Many have taken an interest in penny stocks over the last year....
Penny Stocks · 04/02 20:09
8-K: Arbutus Biopharma Corp
(EDGAR Online via COMTEX) -- 0001447028 False 0001447028 2021-04-01 2021-04-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 04/01 16:34
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ABUS. Analyze the recent business situations of Arbutus Biopharm through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ABUS stock price target is 6.11 with a high estimate of 10.00 and a low estimate of 3.750.
EPS
Institutional Holdings
Institutions: 117
Institutional Holdings: 24.81M
% Owned: 25.75%
Shares Outstanding: 96.34M
TypeInstitutionsShares
Increased
22
2.43M
New
28
1.22M
Decreased
12
1.78M
Sold Out
12
3.70M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.98%
Pharmaceuticals & Medical Research
+0.89%
Key Executives
Chairman/Independent Director
Frank Torti
President/Chief Executive Officer/Director
William Collier
Chief Financial Officer
David Hastings
Executive Vice President/Chief Compliance Officer/General Counsel
Elizabeth Howard
Chief Scientific Officer
Michael Sofia
Other
Michael McElhaugh
Other
Gaston Picchio
Independent Director
Daniel Burgess
Independent Director
Andrew Cheng
Independent Director
Richard Henriques
Independent Director
Keith Manchester
Independent Director
James Meyers
Independent Director
Eric Venker
No Data
  • All
  • Financials
  • Insiders
More
About ABUS
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing cure for people with chronic hepatitis B virus (HBV) infection. Its product pipeline is focused on finding curative combination regimen for chronic HBV infection, with the objective of developing a suite of products that intervene at different points in the viral life cycle and reactivate the host immune system. It is developing a product pipeline consisting of multiple drug candidates with complementary mechanisms of action. The Company’s HBV product pipeline includes ribonucleic acid (RNA) interference (RNAi) therapeutics, oral capsid inhibitors, oral compounds that inhibit programmed death-ligand one (PDL1) and oral HBV RNA destabilizers. Its subsidiaries include Arbutus Inc and Arbutus Biopharma US Holdings, Inc.

Webull offers kinds of Arbutus Biopharma Corp stock information, including NASDAQ:ABUS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ABUS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ABUS stock methods without spending real money on the virtual paper trading platform.